In 2007, the most popular diabetes drug at the time, Avandia, was met with harsh criticism after a cardiologist at the Cleveland Clinic claimed that the drug increased heart attack risk by 43 percent. Shortly thereafter, the drug company that manufactures Avandia, GlaxoSmithKline, issued a report showing that the claim was untrue and there was no increased risk when taking the drug. Nevertheless, the Food and Drug Administration decided to impose strict regulations on the use of Avandia in 2010. The FDA also decided to have another analysis conducted by Duke University. That study showed results similar to the one performed by GlaxoSmithKline, that there was no increased risk of heart attack. These results may lead the FDA to scale back on the restrictions imposed on the drug, allowing it to be more freely prescribed. However, there are now numerous other diabetes drugs on the market that increased in popularity after Avandia's decline and the likelihood that doctors will now begin prescribing Avandia is low.